Department of Urology, Victoria Hospital, University of Western Ontario, 800 Commissioners Road, London, Ontario N6A AG5, Canada.
Expert Rev Anticancer Ther. 2010 Jan;10(1):33-40. doi: 10.1586/era.09.162.
High-intensity focused ultrasound (HIFU) has evolved significantly from early work treating cerebral lesions. The ability to treat deep soft-tissue lesions without damaging superficial structures led to it being used for prostate cancer treatment both in the primary and salvage setting. Primary HIFU treatment for prostate cancer leads to 5-year disease free survival rates of up to 70-80% in selected patients with little morbidity; however, comparative studies with established treatment modalities are lacking. Salvage treatment with HIFU leads to significantly more morbidity than primary treatment yet the morbidity appears the same or less than other salvage treatments following external-beam radiation treatment. We believe that with the development of more advanced imaging techniques combined with multimodality prostate imaging that HIFU's future lies in focal treatment of prostate cancer.
高强度聚焦超声(HIFU)从早期治疗脑部病变的工作中已经有了显著的发展。由于能够治疗深部软组织病变而不损伤浅表结构,因此它被用于前列腺癌的治疗,无论是在原发还是挽救性治疗中。在选择的患者中,HIFU 对前列腺癌的原发治疗可达到 5 年无病生存率高达 70-80%,且发病率较低;然而,与既定治疗方法的比较研究却很少。与原发治疗相比,HIFU 的挽救性治疗导致更多的发病率,但在接受外照射治疗后,其发病率与其他挽救性治疗相同或更低。我们相信,随着更先进的成像技术与多模态前列腺成像技术的发展,HIFU 的未来在于前列腺癌的局灶性治疗。